Giuseppe
Emeritus
Emerging Influenza Antiviral Resistance Threats (J Infect Dis., extract, edited)
[Source: Journal of Infectious Diseases, full PDF document, (LINK). Extract, edited.]
Emerging Influenza Antiviral Resistance Threats
Frederick G. Hayden 1 and Menno D. de Jong 2
1 Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia and International Activities, Science Funding, Wellcome Trust, London, United Kingdom; and
2Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
(See the articles by Sheu et al, on pages 13?17, Moore et al, on pages 18?24, and Pizzorno et al, on pages 25?31.)
Received and accepted 23 September 2010.
FGH: No research grants or personal honoraria from industry for lectures, consulting, or other activities since 2006. Member of Neuraminidase Inhibitor Susceptibility Network with honoraria to University of Virginia since 2008 (funding of NISN from GSK and Roche).
Dr Hayden has served as an uncompensated advisor to multiple companies involved in the development of influenza antivirals since 2008.
(See the articles by Sheu et al, on pages 13?17, Moore et al, on pages 18?24, and Pizzomo et al, on pages 25?31.)
Reprints or correspondence: Dr Frederick G. Hayden, Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, VA 22908; International Activities, Science Funding, Wellcome Trust, London NW1 2BE, United Kingdom (fgh@virginia.edu, f.hayden@wellcome.ac.uk).
The Journal of Infectious Diseases 2011;203:6?10
Copyright, The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com
1537-6613/2011/2031-0001$15.00
DOI: 10.1093/infdis/jiq012
Antiviral resistance in influenza may not only develop during treatment but also sometimes transmit widely to replace susceptible strains in the absence of drug pressure. This transmission is exemplified by the global spread of adamantane-resistant A(H3N2) viruses since 2003, oseltamivir-resistant seasonal A(H1N1) viruses since 2007, and adamantane-resistant pandemic A(H1N1) viruses in 2009, events that emphasize the unpredictability of influenza viruses and the increasing challenges of clinical management of influenza, especially given the current paucity of therapeutic choices.
(...)
-
------
[Source: Journal of Infectious Diseases, full PDF document, (LINK). Extract, edited.]
Emerging Influenza Antiviral Resistance Threats
Frederick G. Hayden 1 and Menno D. de Jong 2
1 Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia and International Activities, Science Funding, Wellcome Trust, London, United Kingdom; and
2Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
(See the articles by Sheu et al, on pages 13?17, Moore et al, on pages 18?24, and Pizzorno et al, on pages 25?31.)
Received and accepted 23 September 2010.
FGH: No research grants or personal honoraria from industry for lectures, consulting, or other activities since 2006. Member of Neuraminidase Inhibitor Susceptibility Network with honoraria to University of Virginia since 2008 (funding of NISN from GSK and Roche).
Dr Hayden has served as an uncompensated advisor to multiple companies involved in the development of influenza antivirals since 2008.
(See the articles by Sheu et al, on pages 13?17, Moore et al, on pages 18?24, and Pizzomo et al, on pages 25?31.)
Reprints or correspondence: Dr Frederick G. Hayden, Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, VA 22908; International Activities, Science Funding, Wellcome Trust, London NW1 2BE, United Kingdom (fgh@virginia.edu, f.hayden@wellcome.ac.uk).
The Journal of Infectious Diseases 2011;203:6?10
Copyright, The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com
1537-6613/2011/2031-0001$15.00
DOI: 10.1093/infdis/jiq012
Antiviral resistance in influenza may not only develop during treatment but also sometimes transmit widely to replace susceptible strains in the absence of drug pressure. This transmission is exemplified by the global spread of adamantane-resistant A(H3N2) viruses since 2003, oseltamivir-resistant seasonal A(H1N1) viruses since 2007, and adamantane-resistant pandemic A(H1N1) viruses in 2009, events that emphasize the unpredictability of influenza viruses and the increasing challenges of clinical management of influenza, especially given the current paucity of therapeutic choices.
(...)
-
------